Key Conferences Shape the Future of Cell and Gene Therapy

Joe DePinto, MBA, Head of Cell, Gene, and Advanced Therapies at McKesson Pharmaceutical Solutions and Services, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with partners to support it effectively.

DePinto also points to significant upcoming meetings, such as the 2024 American Society of Hematology Annual Meeting (ASH) and Exposition and the Advanced Therapies meeting that will take place in January, where the latest clinical data and partnerships will be discussed. These upcoming meetings and more will play a crucial role in furthering efforts in this space.

Transcription:

0:09 | There are 2 big meetings for cell and gene therapy coming up. ASH has a lot of strong clinical data around CD19 BCMA products, as well as the next generation of cell and gene therapies and how they are being examined and explored clinically. That is great. Then, we come back after the holiday break in January, and we have the advanced therapies meeting, which is always a great meeting. It is more of a partnership meeting.

0:39 | The cell and gene ecosystem is complex, even for a company the size of McKesson, we could not possibly be able to support the entire ecosystem. We have a series of partnerships with key providers of unique solutions and services. We are really interested in that meeting to further solidify our partnerships at the advanced therapies meeting in January. And then before you know it, it will be ASCO again, and more clinical data and oncology will be coming out with more approvals. And this year coming up, we anticipate 10 to 20 approvals every year from now through 2030 at least. And that has been validated by some prognostication from FDA leadership in the past. So that is what is exciting in the next months ahead.